Onestopmesothelioma!!
  • General Information 1
    • Asbestos Survey Video
    • Asbestos Support in Wales
    • Help at Hasag
    • Take a Break Page 1 >
      • IATP mavis Award
    • British Uralite
    • A Womans Page
    • Comand Report
    • Royal Marsden Magazine
    • Whitstable Gazette
    • Oncology Forum Program
  • General Info 2
    • Asbestos video Awareness
    • The man Behind Mavis:-
    • Asbestos in Ships
    • Rays Blog
    • HSE at Work
    • Mavis Blog
  • Our Books
    • More Book Info.
  • Inforative Information
    • Asbestos Justice
    • Clinical Trials >
      • Maps of Trial centres
      • MK3475
      • Adams Trial
      • The Warm Chemo Trial
      • Frontiers in Oncology
      • Blocking The Pathway
      • Trials .Gov
      • A Meso Postmortem
      • Studies Good & Bad
      • Meso Report Study
      • Genes Linked to meso
      • Surving Mesothelioma.
    • Difuse Meso Payments
    • Before you Fly!
    • Help on Compensation >
      • Legal Compensation
    • Research Group
    • Treatment Centres
  • Interesting Information.
    • Is Meso Hereditary
    • Why Dont we all get Cancer
    • Armley UK Deadliest Town
    • A Meso Statement.
    • Myths on Mesothelioma.
    • Genes Linked to Meso Cancer
    • NHS Choices.
    • Your CT Scan >
      • More on CT/Pet Scans
    • Sex Is Good for You
    • Saatchi Bill >
      • Saatchi Bill 1
      • Saatchi Bill 2
      • mavis and The Saatchi Bill.
      • The Bill
  • Dust to Dust
Picture
  • Journal List
  • Front Oncol
  • v.1; 2011
  • PMC3364459
Front Oncol. 2011; 1: 22. Published online 2011 August 22. doi:  10.3389/fonc.2011.00022PMCID: PMC3364459Investigational Approaches for MesotheliomaVeerle F. Surmont,1 Eric R. E. van Thiel,2 Karim Vermaelen,1 and Jan P. van Meerbeeck1,*Author information ► Article notes ► Copyright and License information ►Go to:AbstractMalignant pleural mesothelioma (MPM) is a rare, aggressive tumor with a poor prognosis. In view of the poor survival benefit from first-line chemotherapy and the lack of subsequent effective treatment options, there is a strong need for the development of more effective treatment approaches for patients with MPM. This review will provide a comprehensive state of the art of new investigational approaches for mesothelioma. In an introductory section, the etiology, epidemiology, natural history, and standard of care treatment for MPM will be discussed. This review provide an update of the major clinical trials that impact mesothelioma treatment, discuss the impact of novel therapeutics, and provide perspective on where the clinical research in mesothelioma is moving. The evidence was collected by a systematic analysis of the literature (2000–2011) using the databases Medline (National Library of Medicine, USA), Embase (Elsevier, Netherlands), Cochrane Library (Great Britain), National Guideline Clearinghouse (USA), HTA Database (International Network of Agencies for Health Technology Assessment – INAHTA), NIH database (USA), International Pleural Mesothelioma Program – WHOLIS (WHO Database), with the following keywords and filters: mesothelioma, guidelines, treatment, surgery, chemotherapy, radiotherapy, review, investigational, drugs. Currently different targeted therapies and biologicals are under investigation for MPM. It is important that the molecular biologic research should first focus on mesothelioma-specific pathways and biomarkers in order to have more effective treatment options for this disease. The use of array technology will be certainly an implicit gain in the identification of new potential prognostic or biomarkers or important pathways in the MPM pathogenesis. Probably a central mesothelioma virtual tissue bank may contribute to the ultimate goal to identify druggable targets and to develop personalized treatment for the MPM patients.

Keywords: mesothelioma, chemotherapy, targeted therapy For the full Article Click Here.

Powered by Create your own unique website with customizable templates.